183 related articles for article (PubMed ID: 23449613)
1. Saving orphans: BRAF targeting of histiocytosis.
Heaney ML
Blood; 2013 Feb; 121(9):1487-8. PubMed ID: 23449613
[TBL] [Abstract][Full Text] [Related]
2. Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation.
Haroche J; Cohen-Aubart F; Emile JF; Arnaud L; Maksud P; Charlotte F; Cluzel P; Drier A; Hervier B; Benameur N; Besnard S; Donadieu J; Amoura Z
Blood; 2013 Feb; 121(9):1495-500. PubMed ID: 23258922
[TBL] [Abstract][Full Text] [Related]
3. Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study.
Diamond EL; Subbiah V; Lockhart AC; Blay JY; Puzanov I; Chau I; Raje NS; Wolf J; Erinjeri JP; Torrisi J; Lacouture M; Elez E; Martínez-Valle F; Durham B; Arcila ME; Ulaner G; Abdel-Wahab O; Pitcher B; Makrutzki M; Riehl T; Baselga J; Hyman DM
JAMA Oncol; 2018 Mar; 4(3):384-388. PubMed ID: 29188284
[TBL] [Abstract][Full Text] [Related]
4. The histiocytosis Erdheim-Chester disease is an inflammatory myeloid neoplasm.
Haroche J; Cohen-Aubart F; Charlotte F; Maksud P; Grenier PA; Cluzel P; Mathian A; Emile JF; Amoura Z
Expert Rev Clin Immunol; 2015; 11(9):1033-42. PubMed ID: 26197238
[TBL] [Abstract][Full Text] [Related]
5. Vemurafenib as first line therapy in BRAF-mutated Langerhans cell histiocytosis.
Haroche J; Cohen-Aubart F; Emile JF; Donadieu J; Amoura Z
J Am Acad Dermatol; 2015 Jul; 73(1):e29-30. PubMed ID: 26089069
[No Abstract] [Full Text] [Related]
6. Erdheim-Chester disease.
Haroche J; Arnaud L; Cohen-Aubart F; Hervier B; Charlotte F; Emile JF; Amoura Z
Rheum Dis Clin North Am; 2013 May; 39(2):299-311. PubMed ID: 23597965
[TBL] [Abstract][Full Text] [Related]
7. Major response to vemurafenib in patient with severe cutaneous Langerhans cell histiocytosis harboring BRAF V600E mutation.
Charles J; Beani JC; Fiandrino G; Busser B
J Am Acad Dermatol; 2014 Sep; 71(3):e97-9. PubMed ID: 25128147
[No Abstract] [Full Text] [Related]
8. Erdheim-Chester disease associated with a novel, complex BRAF p.Thr599_Val600delinsArgGlu mutation.
Bentel JM; Thomas MA; Rodgers JJ; Arooj M; Gray E; Allcock R; Fermoyle S; Mancera RL; Cannell P; Parry J
BMJ Case Rep; 2017 Apr; 2017():. PubMed ID: 28455460
[TBL] [Abstract][Full Text] [Related]
9. Erdheim Chester disease with appendicular skeletal, renal and pleural involvement responding to Zelboraf (BRAF inhibitor) treatment: case report.
Borys D; Nystrom L; Song A; Lomasney LM
Skeletal Radiol; 2016 Oct; 45(10):1397-402. PubMed ID: 27423231
[TBL] [Abstract][Full Text] [Related]
10. Erdheim-Chester disease.
Campochiaro C; Tomelleri A; Cavalli G; Berti A; Dagna L
Eur J Intern Med; 2015 May; 26(4):223-9. PubMed ID: 25865950
[TBL] [Abstract][Full Text] [Related]
11. Biological and therapeutic implications of the BRAF pathway in histiocytic disorders.
Arceci RJ
Am Soc Clin Oncol Educ Book; 2014; ():e441-5. PubMed ID: 24857137
[TBL] [Abstract][Full Text] [Related]
12. Targeting the BRAF pathway in haematological diseases.
Rees MJ; Dickinson M; Paterson J; Ng TF; Grigg A; Moore J; Blombery P; Seymour JF
Intern Med J; 2023 May; 53(5):845-849. PubMed ID: 37222093
[TBL] [Abstract][Full Text] [Related]
13. Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAF(V600E)-mutated Erdheim-Chester disease.
Haroche J; Cohen-Aubart F; Emile JF; Maksud P; Drier A; Tolédano D; Barete S; Charlotte F; Cluzel P; Donadieu J; Benameur N; Grenier PA; Besnard S; Ory JP; Lifermann F; Idbaih A; Granel B; Graffin B; Hervier B; Arnaud L; Amoura Z
J Clin Oncol; 2015 Feb; 33(5):411-8. PubMed ID: 25422482
[TBL] [Abstract][Full Text] [Related]
14. Low-dose vemurafenib monotherapy in
Ruan GJ; Hazim A; Abeykoon JP; Scheckel C; Vassallo R; Ryu JH; Tobin WO; Koster MJ; Bennani NN; Rech KL; Young JR; Shah MV; Goyal G; Go RS
Leuk Lymphoma; 2020 Nov; 61(11):2733-2737. PubMed ID: 32608295
[No Abstract] [Full Text] [Related]
15. Dramatic efficacy of dabrafenib in Erdheim-Chester disease (ECD): a pediatric patient with multiple large intracranial ECD lesions hidden by refractory Langerhans cell histiocytosis.
Hao X; Feng R; Bi Y; Liu Y; Li C; Lu T; Tian Y
J Neurosurg Pediatr; 2018 Sep; 23(1):48-53. PubMed ID: 30265230
[TBL] [Abstract][Full Text] [Related]
16. A cytologic diagnosis of BRAF
Chasseur P; Kyriakopoulou M; Vokaer B; Beukinga I; Casado Arroyo R; Cogan E; Couturier B
Acta Clin Belg; 2017 Oct; 72(5):369-371. PubMed ID: 28222655
[TBL] [Abstract][Full Text] [Related]
17. Orbital MRI Pre- and Post-Vemurafenib Therapy for Erdheim-Chester Disease.
Grumbine FL; Aderman C; Vagefi MR; Kersten RC
Ophthalmic Plast Reconstr Surg; 2015; 31(6):e169. PubMed ID: 25886699
[No Abstract] [Full Text] [Related]
18. Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.
Hyman DM; Puzanov I; Subbiah V; Faris JE; Chau I; Blay JY; Wolf J; Raje NS; Diamond EL; Hollebecque A; Gervais R; Elez-Fernandez ME; Italiano A; Hofheinz RD; Hidalgo M; Chan E; Schuler M; Lasserre SF; Makrutzki M; Sirzen F; Veronese ML; Tabernero J; Baselga J
N Engl J Med; 2015 Aug; 373(8):726-36. PubMed ID: 26287849
[TBL] [Abstract][Full Text] [Related]
19. Mixed Langerhans Cell Histiocytosis and Erdheim-Chester Disease in a Girl: A Rare and Puzzling Diagnosis.
Ocak S; Bayramoglu Z; Tugcu D; Karaman S; Unuvar A; Karakas Z
J Pediatr Hematol Oncol; 2021 Apr; 43(3):e375-e379. PubMed ID: 32097280
[TBL] [Abstract][Full Text] [Related]
20. Erdheim-Chester disease.
Haroche J; Arnaud L; Cohen-Aubart F; Hervier B; Charlotte F; Emile JF; Amoura Z
Curr Rheumatol Rep; 2014 Apr; 16(4):412. PubMed ID: 24532298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
